Singapore markets closed

Sino Biopharmaceutical Limited (1177.HK)

HKSE - HKSE Delayed price. Currency in HKD
Add to watchlist
2.730-0.060 (-2.15%)
At close: 04:08PM HKT

Sino Biopharmaceutical Limited

Unit 09, Office Tower
41st Floor, Room 4109 Convention Plaza 1 Harbour Road
Wan Chai
Hong Kong
852 2802 9886

Full-time employees25,806

Key executives

NameTitlePayExercisedYear born
Ms. Y. Y. TseExecutive Chairwoman of the Board42.96MN/A1992
Ms. Cheung Ling ChengExecutive Vice Chairwoman of the Board38.11MN/A1964
Ms. Mingqin LiSenior VP & Executive Director1.3MN/A1959
Mr. Zhoushan TianExecutive Director2.03MN/A1964
Mr. Hsin TseSenior VP & Executive Director6.53MN/A1970
Mr. Eric S. Y. TseCEO & Executive Director25.01MN/A1996
Mr. Ping TseFounder & Senior Executive Vice Chairman45.41MN/A1952
Ms. Chun Ling LiChief Financial OfficerN/AN/A1972
Sean ChenChief Strategy OfficerN/AN/AN/A
Orphanides GeorgeChief Scientific Advisor of invoXN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.


Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines comprising Qingkeshu tablets, Focus V capsules, Annike injection, and Anyue capsules; liver disease medicines, including Tianqing ganmei injection and Runzhong dispersible tablets; and respiratory system medicines, such as Tianqing suchang suspension for inhalation and Tianyun for injection. It also provides surgery/analgesia medicines comprising Debaian cataplasms and Gaisanchun soft capsules; and cardio-cerebral vascular medicines, including Yilunping and Kaina tablets. In addition, the company is involved in the long term investments; and healthcare and hospital business. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.

Corporate governance

Sino Biopharmaceutical Limited’s ISS governance QualityScore as of 1 April 2024 is 7. The pillar scores are Audit: 4; Board: 2; Shareholder rights: 7; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.